The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327 (R237) synthetic antibiotic, which will be used to treat urinary tract infection (UTI) and urosepsis.

The four subjects were dosed by fast infusion, receiving 3,000 milligrams (mg) of R237 over 20 minutes.

The cohort testing was part of a wider program for Recce’s Phase I/II UTI/Urosepsis clinical trial, evaluating the drug at fast infusion rates, and work is now set to begin on data evaluation and review – to be undertaken by an Independent Safety Committee – and recruitment for the next testing cohort.

After that, Recce will progress to a Phase II UTI/Urosepsis efficacy trial for the drug, hoping to establish it as a frontline treatment for these conditions.

CEO James Graham said the results moved Recce one step close to achieving this goal.

“Completing dosing for our latest cohort marks another milestone in our journey advancing R327 as a potential frontline treatment for UTI/Urosepsis,” he said.

“We are dedicated to delivering impactful solutions to combat infectious diseases and improve global health outcomes globally.”

The value of R237 derives from the fact that administration of antibiotics through rapid intravenous infusions has been shown to impact patient treatment, wait times, and nursing workloads globally.

Recce Pharmaceuticals is trading at 44c.

RCE by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: RBA keeps rates on hold amid sticky inflation | November 5, 2024

The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus…
The Market Online Video

Timing will be everything for ‘smashing’ Hot Stock tip Judo Capital Holdings

Australian bank Judo Capital Holdings (ASX:JDO), best known for its finance and credit for small and medium-sized businesses, is
The Market Online Video

‘We’re looking’: Nickel-rich Indonesia sounds graphite warning to Aus producers

Nickel-rich Indonesia muscles in on Australian graphite producers as the Southeast Asian country expands into downstream…
Confused man

Aussie inflation seemingly hit a 3 year low. So why’s the ASX200 red?

Headline inflation in Australia has fallen to 2.8%, and that officially takes us into the RBA's…